Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Kenneth P. Olive

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3392-8994; OpenAlex author ID A5028724731; NIH RePORTER profile ID 3127300. Sources: funder_awards.

Their work

Papers
52 (first author 6, last author 10)
Trials
0
Grants
10
Labs led
2
Collaborators
219
Papers, trials and grants by year

2011: 1 paper, 2 grants · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers, 2 grants · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: 9 papers · 2020: 5 papers, 1 grant · 2021: 5 papers · 2022: 2 papers, 1 grant · 2023: 5 papers · 2024: 6 papers · 2025: 1 paper · 2026: 7 papers, 4 grants

Papers 50 of 52

  1. Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. Co-author DOI 10.1007/s11523-026-01236-x↗
  2. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  3. Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2025.101312↗
  4. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  5. Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer. Co-author DOI 10.1038/s41588-026-02714-8↗
  6. Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
  7. PHGDH is a targetable driver of PDAC progression Co-author DOI 10.64898/2026.03.11.711147↗
  8. Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic… Co-author DOI 10.1200/oa-25-00099↗
  9. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Last author DOI 10.1038/s41586-024-07379-z↗
  10. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Last author DOI 10.1038/s41586-024-08084-7↗
  11. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  12. “Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug” Last author DOI 10.1101/2024.05.02.592216↗
  13. Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Co-author DOI 10.1158/0008-5472.can-24-2860↗
  14. Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression. Last author DOI 10.1158/2159-8290.cd-23-0240↗
  15. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biopha.2022.114162↗
  16. Generation and ex vivo culture of murine and human pancreatic ductal adenocarcinoma tissue slice explants. Last author DOI 10.1016/j.xpro.2023.102711↗
  17. Transfusion of salvaged red blood cells during pancreatic ductal adenocarcinoma operations. Co-author DOI 10.1093/bjs/znac393↗
  18. Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer Last author DOI 10.1101/2023.03.19.533333↗
  19. Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.12.24.573257↗
  20. Generation of orthotopic patient-derived xenograft models for pancreatic cancer using tumor slices. Last author DOI 10.1016/j.xpro.2022.101899↗
  21. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  22. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2020.12.029↗
  23. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Co-author DOI 10.1038/s41467-021-24859-2↗
  24. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Co-author DOI 10.1136/gutjnl-2019-319912↗
  25. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  26. Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic… Co-author DOI 10.3390/cancers13071535↗
  27. HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. Co-author DOI 10.1016/j.yexcr.2020.111960↗
  28. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1101/gr.257550.119↗
  29. A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Canc… Co-author DOI 10.1158/0008-5472.can-20-0285↗
  30. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1359↗
  31. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elast… Co-author DOI 10.7150/thno.37965↗
  32. Modeling Pancreatic Cancer through Somatic Editing with AAV. First author DOI 10.1016/j.molmed.2019.02.012↗
  33. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition. Co-author DOI 10.1016/j.trsl.2018.12.008↗
  34. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-12657-w↗
  35. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-13151-z↗
  36. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2017-314353↗
  37. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Last author DOI 10.1136/gutjnl-2018-317706↗
  38. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  39. Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-18-3281↗
  40. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Co-author DOI 10.1177/1758835919841233↗
  41. Technical Note: In vivo Young's modulus mapping of pancreatic ductal adenocarcinoma during HIFU ablation using harmonic motion elastography (HME). Co-author DOI 10.1002/mp.13170↗
  42. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  43. Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma Last author DOI 10.1101/288779↗
  44. Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field. First author DOI 10.1158/0008-5472.can-16-2452↗
  45. Current and Emerging Therapies in Metastatic Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-16-2319↗
  46. Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Co-author DOI 10.1093/carcin/bgv058↗
  47. Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic m… Co-author DOI 10.1109/tuffc.2015.007113↗
  48. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2014.04.021↗
  49. Pancreatic cancer: why is it so hard to treat? First author DOI 10.1177/1756283x13478680↗
  50. Silencing the killers: paracrine immune suppression in pancreatic cancer. First author DOI 10.1016/j.ccr.2012.05.029↗

Grants 10

  1. Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer R01CA215607↗
  2. Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer R01CA266558↗
  3. Adaptation and Evolution of Resistance to Pan-RAS inhibition in PDAC R01CA300785↗
  4. Elucidation and targeting of paracrine cascades in PDAC U01CA274312↗
  5. Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer AWARD pancan:2022-kenneth-olive-phd-therapeutic-induction-of-tumor-selective
  6. Therapeutic Induction of Tumor Selective Ferroptosis in Pancreatic Cancer AWARD pancan:2020-kenneth-olive-phd-therapeutic-induction-of-tumor-selective
  7. Mechanisms of the Stromal Response to Smoothened Inhibition in Pancreatic Cancer R01CA157980↗
  8. Preclinical evaluation of a targeted Bmi1 inhibitor in pancreatic cancer R21CA188857↗
  9. The Role of HIF1 and Hypoxia in Pancreatic Ductal Adenocarcinoma AWARD pancan:2011-kenneth-olive-phd-the-role-of-hif1-and-hypoxia-in-pancreat
  10. Micro Ultrasound Scanner to Track Tumor Models S10RR025482↗

Closest collaborators

The 25 strongest of 219 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gulam Abbas Manji · 7 shared papers, 2 shared grants, 2017–2026 · strength 3.62
  2. H. Carlo Maurer · 20 shared papers, 2018–2026 · strength 2.40
  3. Alina Cornelia Iuga · 10 shared papers, 2018–2026 · strength 1.30
  4. Álvaro Curiel‐García · 6 shared papers, 2019–2026 · strength 1.11
  5. Marie C. Hasselluhn · 5 shared papers, 2024–2026 · strength 0.94
  6. Amanda R. Decker-Farrell · 5 shared papers, 2019–2024 · strength 0.93
  7. Andrea Califano · 6 shared papers, 2018–2026 · strength 0.85
  8. Marina Pasca di Magliano · 5 shared papers, 2015–2026 · strength 0.67
  9. Susan Elaine Bates · 3 shared papers, 2026 · strength 0.62
  10. John A. Chabot · 5 shared papers, 2018–2026 · strength 0.60
  11. Maximilian Reichert · 4 shared papers, 2018–2026 · strength 0.59
  12. Urszula N. Wasko · 3 shared papers, 2024–2026 · strength 0.58
  13. Christoph Benedikt Westphalen · 5 shared papers, 2012–2026 · strength 0.56
  14. Michael S. May · 3 shared papers, 2023–2026 · strength 0.56
  15. Alexander Grenander Raufi · 3 shared papers, 2023–2026 · strength 0.56
  16. Michael D. Kluger · 3 shared papers, 2020–2026 · strength 0.46
  17. Beth Schrope · 3 shared papers, 2020–2026 · strength 0.46
  18. Paul E. Oberstein · 6 shared papers, 2013–2020 · strength 0.45
  19. Michael A. Badgley · 3 shared papers, 2021–2024 · strength 0.43
  20. Tito Fojo · 2 shared papers, 2026 · strength 0.42
  21. Anirban Maitra · 2 shared papers, 2024–2026 · strength 0.42
  22. Pasquale Laise · 3 shared papers, 2019–2026 · strength 0.42
  23. Alexander Muir · 2 shared papers, 2023–2024 · strength 0.40
  24. Linda Y. Wu · 2 shared papers, 2026 · strength 0.39
  25. Benjamin Izar · 2 shared papers, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.